Precigen, Inc. shares rise 1.29% premarket after FDA approval of novel immunotherapy and Cencora's support for commercial launch.

Precigen, Inc. rose 1.29% in premarket trading, with the company's recent approval of a novel immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis (RRP) by the U.S. Food and Drug Administration. Cencora, a global pharmaceutical solutions organization, has been selected to provide comprehensive logistics and distribution services to support the commercial launch of Precigen's immunotherapy in the United States.